Molecule

Think Bioscience Appoints Wendy Young, Ph.D., to its Scientific Advisory Board

Retrieved on: 
Monday, October 30, 2023
Molecule, American Cancer Society, Genomics, Therapy, Scio Diamond Technology Corporation, GV (company), Wake Forest University, Medicinal chemistry, Research, Protein, Journal, Journal of Medicinal Chemistry, Senior, Princeton University, Celera Corporation, Memorial Sloan Kettering Cancer Center, Multiple sclerosis, Genentech, BTK, Chemistry, Patient, Coronavirus Scientific Advisory Board, Pharmaceutical industry, List of life sciences

BOULDER, Colo., Oct. 30, 2023 /PRNewswire/ -- Think Bioscience ("Think"), a Boulder-based synthetic biology company focused on developing small-molecule therapeutics that target "undruggable" proteins, has appointed Wendy Young, Ph.D., to its Scientific Advisory Board. Dr. Young is a seasoned pharmaceutical professional with 30+ years of experience in small molecule research and development

Key Points: 
  • Think Bioscience brings on accomplished biotech executive and drug discovery veteran Wendy Young, Ph.D.
    BOULDER, Colo., Oct. 30, 2023 /PRNewswire/ -- Think Bioscience ("Think"), a Boulder-based synthetic biology company focused on developing small-molecule therapeutics that target "undruggable" proteins, has appointed Wendy Young , Ph.D., to its Scientific Advisory Board.
  • "We are excited to leverage her deep expertise to build Think into an industry-leading research and development organization."
  • Dr. Young currently serves as a director and/or scientific advisor to several biotech companies and is an advisor at Google Ventures.
  • "I'm excited by the elegance of the Think Bioscience platform, which can discover new functional binding sites and access novel chemical matter.

PAAMCO PRISMA JOINS ARCESIUM TECHNOLOGY PLATFORM

Retrieved on: 
Monday, October 30, 2023
Treasury, PAAMCO, Sleeve, Risk, Partnership, Partner, Prisma, Security (finance), Molecule

NEW YORK, Oct. 30, 2023 /PRNewswire/ -- Arcesium LLC, a leading global financial technology firm, announced today that alternative investment firm, PAAMCO Prisma, chose Arcesium's Treasury Suite to optimize its treasury management. Arcesium's treasury capabilities are designed to provide enhanced transparency and control over PAAMCO Prisma's collateral management and securities lending. With advanced margin replication and simulation strategies, Arcesium's solutions are engineered to enable PAAMCO Prisma to optimize multi-asset collateral allocation for their multi-strategy platform, Molecule.

Key Points: 
  • PAAMCO Prisma Selects Arcesium to Strengthen Treasury, Margin, and Collateral Operations
    NEW YORK, Oct. 30, 2023 /PRNewswire/ -- Arcesium LLC, a leading global financial technology firm, announced today that alternative investment firm, PAAMCO Prisma, chose Arcesium's Treasury Suite to optimize its treasury management.
  • Arcesium's treasury capabilities are designed to provide enhanced transparency and control over PAAMCO Prisma's collateral management and securities lending.
  • With advanced margin replication and simulation strategies, Arcesium's solutions are engineered to enable PAAMCO Prisma to optimize multi-asset collateral allocation for their multi-strategy platform, Molecule.
  • We're thrilled to work with PAAMCO Prisma to optimize their operations and help address their most pressing challenges."

Global Small Molecule Innovator CDMO Market Poised for Strong 6.5% CAGR Through 2031, Fueled by Rising Outsourcing Demand in Pharmaceutical Development - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 18, 2023
Other Science, Science, Molecule, Drug development, Pharmaceutical innovations, Infection, Metabolic disorder, Lonza Group, Catalent, Confidentiality, Small molecule, Therapy, Recipharm, Johnson & Johnson Pharmaceutical Research and Development, Patheon, European Journal of Pharmaceutical Sciences, Neurology, Metabolism, CDMO, Research, Journal, Outsourcing, Pharmacy, Growth, Respiratory disease, COVID-19, Commercial, Cardiovascular disease, Cambrex Corporation, Thermo Fisher Scientific, Clinical pharmaceutical scientist, Small, Flexible, Intellectual property, IP, Compound annual growth rate, AAPS, Fine chemical, Pharmaceutical industry, Biotechnology

Increasing Demand for Outsourcing Services in Drug Development: Pharmaceutical companies are increasingly outsourcing complex and resource-intensive processes such as drug substance synthesis and drug product manufacturing to CDMOs.

Key Points: 
  • Increasing Demand for Outsourcing Services in Drug Development: Pharmaceutical companies are increasingly outsourcing complex and resource-intensive processes such as drug substance synthesis and drug product manufacturing to CDMOs.
  • Intellectual Property and Confidentiality Concerns: Intellectual property (IP) and confidentiality concerns pose a restraint on the Small Molecule Innovator CDMO market.
  • The Small Molecule Innovator CDMO market is segmented into product types, stage types, customer types, therapeutic areas, and regions.
  • Notable segments include:
    Product: Small Molecule API and Small Molecule Drug Product, with Small Molecule API exhibiting the highest CAGR during the forecast period.

Adiso Therapeutics Announces Positive Topline Data from Phase 1b Study of ADS051 for the Treatment of Moderate-to-Severe Ulcerative Colitis

Retrieved on: 
Sunday, October 22, 2023
Molecule, FDA, Trial of the century, American College, Harvard Medical School, Crohn's disease, UC, ACG, Naval Hospital Boston, Inflammation, Pathology, Safety, MAD, American College of Gastroenterology, SAD, Ulcerative colitis, Clinical trial, FPR1, MRP2, Therapy, Associate, Pharmaceutical industry, Patient, Medicine

CONCORD, Mass., Oct. 22, 2023 /PRNewswire/ -- Adiso Therapeutics, Inc., a clinical-stage biotechnology company committed to creating medicines that treat inflammatory diseases and improve the lives of patients and their families, today announced positive topline data from its Phase 1b multiple ascending dose (MAD) clinical trial evaluating ADS051 (BT051) in patients with moderate-to-severe ulcerative colitis (UC). The data were presented today at the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting being held October 20-25, in Vancouver, Canada.

Key Points: 
  • ADS051 is a first-in-class, oral, gut-restricted, small molecule modulator of neutrophil trafficking and activation via inhibition of MRP2 and FPR1.
  • The randomized, double-blind, placebo-controlled, MAD Phase 1b study enrolled 24 moderately-to-severely active UC patients, all of whom completed the trial as planned over the 28-day treatment period ( NCT05084261 ).
  • "ADS051 efficacy measures reveal encouraging signals of pharmacologic activity and clinical benefit versus placebo, after 28 days of treatment.
  • Given these findings and a recently completed positive end-of-Phase 1 FDA interaction, we plan to advance ADS051 in a Phase 2 clinical study in early 2024."

ITRI Excels with Eight 2023 R&D 100 Awards, Showcasing Biotechnological Triumph

Retrieved on: 
Wednesday, October 18, 2023
Molecule, Biomedical Research, Electronics, Oak Ridge National Laboratory, Coordination, Intraocular pressure, Ocular hypertension, RFA, Complex, AMD, Pancreas, IOP, Drainage, Injection, Liver, Vance DeGeneres, Infection, CSC, Research, Inflammation, Bleeding, Quality of life, Clinician Administered PTSD Scale, Compal Electronics, Risk, Surgeon, United States Commission on International Religious Freedom, Irritation, ICT, Anxiety, Patient, Macular edema, Breast, ITRI, Pharmaceutical industry, Glaucoma

ITRI's accolades include five net-zero solutions and three novel biomedical technologies, marking a historic win for the institute's biotechnology sector.

Key Points: 
  • ITRI's accolades include five net-zero solutions and three novel biomedical technologies, marking a historic win for the institute's biotechnology sector.
  • "It marks the fifth consecutive year that ITRI's biomedical innovations have earned the prestigious R&D 100 Awards, showcasing the international caliber of Taiwan's biomedical research capabilities," noted ITRI President Edwin Liu.
  • All three award-winning technologies have been transferred to Taiwanese companies, reflecting the Institute's commitment to translating research into practical industrial applications.
  • Beyond its current applications, iRFA's can potentially be extended to breast and orthopedic tumor ablation and even robotic-assisted surgery.

St. Jude Children’s Research Hospital, ALSAC announce new board leaders

Retrieved on: 
Monday, October 16, 2023
American Academy of Orthopaedic Surgeons, Biomedical engineering, Advance Auto Parts, William H. Harris (orthopaedic surgeon), Commerce, National Cancer Institute, Health, Survival, DSM-IV codes, Social media, Rady, Research, UCSD, Infection, NCI-designated Cancer Center, Molecule, Albert Einstein College of Medicine, Montefiore, Columbia University, Greater Boston, History, Neuroscience, Volunteering, Del Monte Foods, International, OfficeMax, Sutter Health, Sickle cell disease, University, Cancer, Stitch Fix, Williams-Sonoma, Inc., Physician, Yale University, National Cancer Research Institute, American Academy, Signet Jewelers, Hospital, Orthopedic surgery, ALSAC, University of California, San Diego, Science, Child, Management, Nursing, Jude the Apostle, Pediatrics

Memphis, Oct. 16, 2023 (GLOBE NEWSWIRE) -- St. Jude Children’s Research Hospital ® and ALSAC , its fundraising and awareness organization, announced new leaders of the St. Jude Board of Governors and ALSAC Board of Directors today.

Key Points: 
  • Memphis, Oct. 16, 2023 (GLOBE NEWSWIRE) -- St. Jude Children’s Research Hospital ® and ALSAC , its fundraising and awareness organization, announced new leaders of the St. Jude Board of Governors and ALSAC Board of Directors today.
  • Having chaired the ALSAC Board of Directors from 2019 to 2021, she is now the first woman to have chaired both Boards.
  • “Sharon’s wise counsel and vast business experience will also be a great asset as vice chair of the ALSAC Board.
  • To learn more, visit stjude.org , read St. Jude Progress blog , and follow St. Jude on social media at @stjuderesearch .

SCIEX OS Software 3.3 Brings Support for QTRAP System Functionality to Entire SCIEX Triple Quadrupole Portfolio

Retrieved on: 
Tuesday, October 10, 2023
Health, Technology, Other Technology, Other Science, Software, Science, Biotechnology, Molecule, DFT, Ecosystem, API, Exploration, Mobile phone, Online shopping, SCIEX

SCIEX , a global leader in life science analytical technologies, announces the launch of SCIEX OS software 3.3.

Key Points: 
  • SCIEX , a global leader in life science analytical technologies, announces the launch of SCIEX OS software 3.3.
  • With this new release, SCIEX OS now supports triple quadrupole linear ion trap ( QTRAP ) technology on the entire nominal mass spectrometry portfolio and provides access to the Dynamic Fill Time (DFT) feature, a tunable parameter designed to further optimize data obtained from QTRAP.
  • SCIEX OS software 3.3 includes significant improvements in the batch and audit workspaces, allowing users to track project modifications with greater reliability.
  • These enhancements further streamline data processing and allow SCIEX OS software users to access their data more efficiently and securely.

Earth Finance Acquires Climate Policy Firm Molecule LLC

Retrieved on: 
Wednesday, October 11, 2023
Molecule, President Clinton, Climate, Acquisition, Intelligence, Private sector, Government, Transport, Carbon, USDA, Entrepreneurship, World Bank, Gates, Policy, Sapphire Energy, Public policy, Science, Aviation, USDOE, White House, Renewable energy

SEATTLE, Oct. 11, 2023 /PRNewswire/ -- Earth Finance, a leading climate strategy and finance firm, today announces the acquisition of Molecule LLC, a Seattle-based climate advocacy firm founded and led by Tim Zenk. Zenk is a well-known industry leader who has worked in government, private sector and entrepreneurial ventures to advance renewable energy and renewable fuels, regenerative agriculture, sustainable aviation fuel, broadband access and carbon reduction programs and policies.

Key Points: 
  • SEATTLE, Oct. 11, 2023 /PRNewswire/ -- Earth Finance, a leading climate strategy and finance firm, today announces the acquisition of Molecule LLC, a Seattle-based climate advocacy firm founded and led by Tim Zenk.
  • Zenk joins as a Managing Director within Earth Finance and now leads Earth Finance's renewable fuels and public policy teams.
  • "Earth Finance's unique model of integrating policy with science and investment is critical to achieving a 1.5-degree future," said Zenk.
  • "The opportunity to scale our work in collaboration with the Earth Finance team is exciting for me, my colleagues, and Molecule's client partners."

1859 Announces the Formation of Its Scientific Advisory Board

Retrieved on: 
Wednesday, October 4, 2023
Alternative Medicine, Health, Technology, Health Technology, Other Health, Artificial Intelligence, Biotechnology, Molecule, SAB, AIML, University, Dean, United States Air Force Scientific Advisory Board, Research, Associate, Chemistry, Graduate, Protein, American Chemical Society, Scripps Research, Carnegie Mellon University, UCSF, ACS, Research fellow, Medicinal chemistry, NVIDIA, Drug discovery, Artificial intelligence, AI, Oligonucleotide, GPU, Pharmaceutical industry

1859, an AI-driven small molecule drug discovery company advancing next generation medicines, announces the establishment of its Scientific Advisory Board (SAB).

Key Points: 
  • 1859, an AI-driven small molecule drug discovery company advancing next generation medicines, announces the establishment of its Scientific Advisory Board (SAB).
  • The board includes scientific co-founder Brian Paegel, Phil Dawson, Michelle Arkin, and Olexandr Isayev.
  • “We are delighted to have our Scientific Advisory Board join the 1859 team.
  • These technologies were foundational to 1859's early screening platform, with 1859 being one of four biotech companies Brian has co-founded.

Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Retrieved on: 
Monday, October 2, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Genetics, Clinical Trials, Biologics license application, Priority review, University, Pediatrics, Molecule, Pharming, Infection, Survival, Skin, MBA, University of California, Disorder, Medication, Șaeș, Molecular genetics, Patient, Cell, Disease, PDUFA, Mortality, Immunology, Principal, UCLA, Pharmacology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BLA, Food, Caregiver, Pharmaceutical industry, Microbiology

“Today’s acceptance of the BLA by the FDA marks a significant milestone for Rocket towards our goal of delivering a one-time gene therapy to patients facing the devastating effects of severe LAD-I.

Key Points: 
  • “Today’s acceptance of the BLA by the FDA marks a significant milestone for Rocket towards our goal of delivering a one-time gene therapy to patients facing the devastating effects of severe LAD-I.
  • All primary and secondary endpoints were met, and RP-L201 was very well tolerated in all patients with no treatment related SAEs.
  • “As the Principal Investigator in the U.S., I oversaw treatment of six of the nine LAD-I patients in this trial.
  • All of these children have been in good health with no significant LAD-I-related infections or inflammatory skin lesions since treatment.